ICOSLG |
ICOS |
||
---|---|---|---|
Gene Name | inducible T-cell co-stimulator ligand | inducible T-cell co-stimulator | |
Image | No pdb structure | No pdb structure | |
Gene Ontology Annotations | Cellular Component | ||
Molecular Function | |||
Biological Process | |||
Pathways | |||
Drugs | |||
Diseases | |||
GWAS | |||
Protein-Protein Interactions | 1 interactors: ICOS | 2 interactors: ICOSLG WIF1 | |
Entrez ID | 23308 | 29851 | |
HPRD ID | 05757 | 09196 | |
Ensembl ID | ENSG00000160223 | ENSG00000163600 | |
Uniprot IDs | A0N0L8 K4DIA0 O75144 | Q53QY6 Q9Y6W8 | |
PDB IDs | |||
Enriched GO Terms of Interacting Partners? |
|
||
Tagcloud ? | atf4
biomarkers
chek2
computational
concept
conjunction
datasets
downregulated
druggable
enah
eventually
identifying
implicate
jimt
methodology
preclinical
progress
proof
rad51
reproducibly
restored
rigorous
rigorously
skbr3
subpathways
transcriptomic
trastuzumab
upregulated
validation
|
aberrant
adaptive
attributed
b7
beneficial
blockade
blocking
cd28
checkpoints
combinatorial
contributions
ctla
evasion
exceptionally
existing
h4
immunity
immunotherapies
immunotherapy
investigating
microenvironment
monotherapies
pd
prompting
rely
responsiveness
restore
substantial
therapeutics
|
|
Tagcloud (Difference) ? | atf4
biomarkers
chek2
computational
concept
conjunction
datasets
downregulated
druggable
enah
eventually
identifying
implicate
jimt
methodology
preclinical
progress
proof
rad51
reproducibly
restored
rigorous
rigorously
skbr3
subpathways
transcriptomic
trastuzumab
upregulated
validation
|
aberrant
adaptive
attributed
b7
beneficial
blockade
blocking
cd28
checkpoints
combinatorial
contributions
ctla
evasion
exceptionally
existing
h4
immunity
immunotherapies
immunotherapy
investigating
microenvironment
monotherapies
pd
prompting
rely
responsiveness
restore
substantial
therapeutics
|
|
Tagcloud (Intersection) ? |